A Retrospective Analysis of the Coagulation Dysfunction in COVID-19 Patients

• Published in: Clinical and applied thrombosis/hemostasis Vol. 26; p. 1076029620964868
• Main Authors: Chen, Xu, Wang, Qinghua, Xu, Min, Li, Chengbin
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 2020; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Adult; Aged; Area Under Curve; Biomarkers; Biomarkers - blood; Blood Coagulation Disorders - blood; Blood Coagulation Disorders - etiology; Blood Coagulation Disorders - physiopathology; Blood Coagulation Tests - methods; China; Cohort Studies; Coronavirus Infections - complications; Coronavirus Infections - diagnosis; Coronaviruses; COVID-19; Female; Fibrin Fibrinogen Degradation Products - analysis; Humans; Male; Middle Aged; Original; Pandemics; Pneumonia, Viral - complications; Pneumonia, Viral - diagnosis; Predictive Value of Tests; Prothrombin Time; Retrospective Studies; ROC Curve; Severity of Illness Index; Thrombin Time; China; blood coagulation factors; coagulation; biomarkers
• ISSN: 1076-0296; 1938-2723
• DOI: 10.1177/1076029620964868

To discuss the coagulation dysfunction in COVID-19 patients and to find new biomarkers to separate severe COVID-19 patients from mild ones. We use a retrospective analysis of 88 COVID-19 patients, and compare the coagulation function between severe and mild groups. We found the prothrombin time (PT), thrombin time (TT), D-dimer were significantly higher in the severe group (P < 0.05), and the highest area under the curve (AUC) is 0.91 for D-dimer, while the AUC of PT and TT were 0.80 and 0.61 respectively. We identified that D-dimer has a better value in predicting patients who are likely to develop into severe cases, with the sensitivity and specificity were 84.4% and 88.8%, respectively. D-dimer may be a good biomarker to separate the severe COVID-19 patients from the mild ones.